| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $7,159 | 2 | 13 |
Sells | $476,096 | 13 | 87 |
| Baldry Mark | Chief Commercial Officer | 2 | $7,159 | 2 | $19,747 | $-12,588 |
| Arbet-Engels Christophe | Chief Medical Officer | 0 | $0 | 1 | $5,284 | $-5,284 |
| Taveras Arthur | Chief Scientific Officer | 0 | $0 | 1 | $43,306 | $-43,306 |
| DiBiase Mary | Chief Operating Officer | 0 | $0 | 3 | $50,161 | $-50,161 |
| Mostafa Adam S. | Chief Financial Officer | 0 | $0 | 2 | $160,848 | $-160,848 |
| Ragan Paula | President and CEO | 0 | $0 | 4 | $196,750 | $-196,750 |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at X4 Pharmaceuticals, Inc. have bought $7,159 and sold $476,096 worth of X4 Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at X4 Pharmaceuticals, Inc. have bought $25,844 and sold $568,260 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Baldry Mark (Chief Commercial Officer) — $7,159.
The last purchase of 1,032 shares for transaction amount of $2,561 was made by Baldry Mark (Chief Commercial Officer) on 2025‑05‑16.
| 2025-05-16 | Baldry Mark | Chief Commercial Officer | 1,032 0.0152% | $2.48 | $2,561 | -6.85% | ||
| 2025-01-24 | Sale | Ragan Paula | President and CEO | 76,473 0.0441% | $0.45 | $34,719 | -60.15% | |
| 2025-01-24 | Sale | DiBiase Mary | Chief Operating Officer | 22,258 0.0128% | $0.45 | $10,094 | -60.15% | |
| 2025-01-24 | Sale | Baldry Mark | Chief Commercial Officer | 29,159 0.0168% | $0.45 | $13,241 | -60.15% | |
| 2025-01-24 | Sale | Arbet-Engels Christophe | Chief Medical Officer | 11,624 0.0067% | $0.45 | $5,284 | -60.15% | |
| 2025-01-24 | Sale | Mostafa Adam S. | Chief Financial Officer | 74,773 0.0431% | $0.45 | $33,947 | -60.15% | |
| 2024-11-15 | Sale | Ragan Paula | President and CEO | 31,897 0.0186% | $0.39 | $12,583 | -25.76% | |
| 2024-11-15 | Baldry Mark | Chief Commercial Officer | 13,404 0.0068% | $0.34 | $4,598 | -25.76% | ||
| 2024-10-15 | Sale | Ragan Paula | President and CEO | 31,897 0.0161% | $0.56 | $17,926 | -38.68% | |
| 2024-10-07 | Sale | Ragan Paula | President and CEO | 239,436 0.1183% | $0.55 | $131,522 | -32.60% | |
| 2024-10-07 | Sale | DiBiase Mary | Chief Operating Officer | 67,695 0.0345% | $0.57 | $38,329 | -32.60% | |
| 2024-10-07 | Sale | Taveras Arthur | Chief Scientific Officer | 76,920 0.0389% | $0.56 | $43,306 | -32.60% | |
| 2024-10-07 | Sale | Baldry Mark | Chief Commercial Officer | 11,127 0.0059% | $0.58 | $6,506 | -32.60% | |
| 2024-10-07 | Sale | Mostafa Adam S. | Chief Financial Officer | 230,645 0.1141% | $0.55 | $126,901 | -32.60% | |
| 2024-09-09 | Sale | DiBiase Mary | Chief Operating Officer | 2,642 0.0016% | $0.66 | $1,738 | -43.03% | |
| 2024-05-17 | Baldry Mark | Chief Commercial Officer | 21,646 0.009% | $0.68 | $14,654 | -38.60% | ||
| 2024-03-11 | Sale | Ragan Paula | President and CEO | 49,678 0.0287% | $0.88 | $43,856 | -25.86% | |
| 2024-03-11 | Sale | DiBiase Mary | Chief Operating Officer | 15,409 0.0089% | $0.88 | $13,591 | -25.86% | |
| 2024-03-11 | Sale | Taveras Arthur | Chief Scientific Officer | 14,235 0.0082% | $0.88 | $12,552 | -25.86% | |
| 2024-03-11 | Sale | Mostafa Adam S. | Chief Financial Officer | 52,500 0.0304% | $0.88 | $46,347 | -25.86% |
| Ragan Paula | President and CEO | 1087386 18.7845% | $1.55M | 0 | 40 | |
| DiBiase Mary | Chief Operating Officer | 490980 8.4816% | $702,101.40 | 0 | 17 | |
| Taveras Arthur | Chief Scientific Officer | 388026 6.7031% | $554,877.18 | 0 | 6 | |
| Baldry Mark | Chief Commercial Officer | 25337 0.4377% | $36,231.91 | 3 | 3 | <0.0001% |
| Arbet-Engels Christophe | Chief Medical Officer | 14207 0.2454% | $20,316.01 | 0 | 1 | |
| Mostafa Adam S. | Chief Financial Officer | 0 0% | $0 | 0 | 21 | |
| GORDON CARL L | 1868966 32.2862% | $2.67M | 1 | 0 | ||
| Ross Michael Jay | 1868961 32.2861% | $2.67M | 1 | 0 | ||
| SVLSF V, LLC | 10 percent owner | 1868961 32.2861% | $2.67M | 1 | 0 | |
| MCGUIRE TERRANCE | 1803429 31.1541% | $2.58M | 1 | 0 | ||
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 1803429 31.1541% | $2.58M | 1 | 0 | |
| NeoMed Innovation V L.P. | 10 percent owner | 867639 14.9884% | $1.24M | 1 | 0 | |
| Nessi Claudio | director | 867639 14.9884% | $1.24M | 1 | 0 | |
| Gerngross Tillman U. | director | 392821 6.786% | $561,734.03 | 1 | 0 | |
| EMBL Technology Fund II GmbH & Co. KG | 10 percent owner | 370454 6.3996% | $529,749.22 | 1 | 0 | |
| Stewart Murray | Interim Chief Medical Officer | 146504 2.5308% | $209,500.72 | 0 | 1 | |
| Meisner Derek M | Chief Legal Officer | 145155 2.5075% | $207,571.65 | 0 | 8 | |
| WYZGA MICHAEL S | director | 76667 1.3244% | $109,633.81 | 1 | 0 | <0.0001% |
| Skerlj Renato | Chief Scientific Officer | 42076 0.7269% | $60,168.68 | 0 | 1 | |
| Cadavid Diego | Chief Medical Officer | 7107 0.1228% | $10,163.01 | 0 | 1 |
$8,253,997 | 122 | -53.40% | $9.88M | |
$63,749,694 | 24 | -12.24% | $6.41M | |
$37,197,670 | 19 | -48.36% | $10.6M | |
$547,862 | 19 | -29.82% | $10.36M | |
$29,469,413 | 18 | 30.40% | $9.18M | |
$1,556,551 | 15 | -25.43% | $7.12M | |
$105,917 | 11 | -28.06% | $8.17M | |
$232,642 | 8 | -8.03% | $9.04M | |
$603,773 | 6 | -56.12% | $8.03M | |
$40,324 | 6 | 31.82% | $7.48M | |
$73,934 | 5 | -39.52% | $9.68M | |
$149,778 | 4 | -45.16% | $6.64M | |
$149,611 | 4 | -25.43% | $10.57M | |
$1,028,395 | 4 | -11.91% | $7.47M | |
$76,299 | 4 | 11.60% | $6.48M | |
$1,057,000 | 3 | 5.27% | $9.54M | |
X4 Pharmaceuticals, Inc. (XFOR) | $44,529 | 2 | -30.33% | $8.28M |
$4,423 | 2 | 3.27% | $7.16M | |
$7,699,992 | 2 | -74.95% | $8.35M |
| Increased Positions | 43 | +43.43% | 390,299 | +11.67% |
| Decreased Positions | 35 | -35.35% | 327,540 | -9.8% |
| New Positions | 16 | New | 57,813 | New |
| Sold Out Positions | 13 | Sold Out | 94,063 | Sold Out |
| Total Postitions | 107 | +8.08% | 3M | +1.88% |
| Bain Capital Life Sciences Investors, Llc | $2,100.00 | 9.4% | 563,803 | 0 | 0% | 2024-12-31 |
| Nea Management Company, Llc | $1,861.00 | 8.32% | 499,510 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $1,419.00 | 6.35% | 380,972 | +12,321 | +3.34% | 2025-03-31 |
| Vanguard Group Inc | $1,018.00 | 4.56% | 273,336 | -7,994 | -2.84% | 2024-12-31 |
| Acorn Capital Advisors, Llc | $908.00 | 4.06% | 243,664 | +243,664 | New | 2024-12-31 |
| Orbimed Advisors Llc | $886.00 | 3.96% | 237,760 | 0 | 0% | 2024-12-31 |
| Kingdon Capital Management, L.L.C. | $613.00 | 2.74% | 164,550 | +9,943 | +6.43% | 2024-12-31 |
| Geode Capital Management, Llc | $434.00 | 1.94% | 116,562 | +1,656 | +1.44% | 2024-12-31 |
| Axa S.A. | $381.00 | 1.71% | 102,395 | -159 | -0.15% | 2024-12-31 |
| State Street Corp | $380.00 | 1.7% | 101,900 | +3,480 | +3.54% | 2024-12-31 |